ad image

Mallinckrodt Pharmaceuticals

1 / 1
BIOVECTRA
Transaction

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

BIOVECTRA

PR-M09-19-NI-037Sep 13, 2019
Mallinckrodt Pharmaceuticals
M&A

Mallinckrodt and Silence Therapeutics Announce Collaboration to Develop And Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Mallinckrodt Pharmaceuticals

PR-M07-19-NI-059Jul 23, 2019
Mallinckrodt Modifies Specialty Generics Spinout Portfolio Composition
Generics

Mallinckrodt Modifies Specialty Generics Spinout Portfolio Composition

Nice Insight

PAO-M06-19-NI-004Jun 13, 2019
Mallinckrodt Pharmaceuticals
Generics

Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders

Mallinckrodt Pharmaceuticals

PR-M05-19-NI-087May 31, 2019
Mallinckrodt Pharmaceuticals
Research

Mallinckrodt Presents Data on Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

Mallinckrodt Pharmaceuticals

PR-M03-19-NI-013Mar 06, 2019
Mallinckrodt Spins off its Generics Business
Spin-off Business

Mallinckrodt Spins off its Generics Business

Pharma's Almanac

PAO-M12-18-NI-005-11Dec 11, 2018
Mallinckrodt Pharmaceuticals
Rheumatology

Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 ACR/ARHP Annual Meeting

Mallinckrodt Pharmaceuticals

PR-M10-18-NI-092Oct 26, 2018
Mallinckrodt Pharmaceuticals
Skin Graft

Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns

Mallinckrodt Pharmaceuticals

PR-M10-18-NI-063Oct 18, 2018
Cancer Prevention Pharmaceuticals
Licensing Agreement

Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt

Cancer Prevention Pharmaceuticals

PR-M09-18-NI-008Sep 05, 2018
Mallinckrodt Pharmaceuticals
Collaborative Research Partnership

Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis

Mallinckrodt Pharmaceuticals

PR-M08-18-NI-056Aug 14, 2018
Mallinckrodt Pharmaceuticals
Clinical Data

Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Mallinckrodt Pharmaceuticals

PR-M07-18-NI-009Jul 03, 2018
Mallinckrodt Pharmaceuticals
Scientific Advisory Council

Mallinckrodt Launches Scientific Advisory Council

Mallinckrodt Pharmaceuticals

PR-M06-18-NI-081Jun 25, 2018
Mallinckrodt Pharmaceuticals
FDA Acceptance

Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-106Feb 28, 2018
Mallinckrodt Pharmaceuticals
Clinical Trials

Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-74Feb 20, 2018
Mallinckrodt Pharmaceuticals
Acquisition

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-62Feb 16, 2018
Mallinckrodt Expands Rare Disease Pipeline with Sucampo Acquisition
Acquistion

Mallinckrodt Expands Rare Disease Pipeline with Sucampo Acquisition

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M01-18-NI-017Jan 11, 2018
Mallinckrodt Expands Pipeline with Ocera Therapeutics Buy
Acquisition

Mallinckrodt Expands Pipeline with Ocera Therapeutics Buy

Nice Insight

PAO-M11-17-NI-020Nov 10, 2017
Mallinckrodt Acquires InfaCare Pharmaceutical Corporation for $425 Million
Acquisition

Mallinckrodt Acquires InfaCare Pharmaceutical Corporation for $425 Million

Nice Insight

PAO-M08-17-NI-023Aug 17, 2017
1 / 1